Gilead Sciences Inc (GILD)
65.98
+1.38
(+2.14%)
USD |
NASDAQ |
May 10, 16:00
65.85
-0.13
(-0.20%)
After-Hours: 20:00
Gilead Sciences Revenue (TTM): 27.45B for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 27.45B |
| December 31, 2023 | 27.12B |
| September 30, 2023 | 27.39B |
| June 30, 2023 | 27.38B |
| March 31, 2023 | 27.04B |
| December 31, 2022 | 27.28B |
| September 30, 2022 | 27.14B |
| June 30, 2022 | 27.52B |
| March 31, 2022 | 27.47B |
| December 31, 2021 | 27.30B |
| September 30, 2021 | 27.48B |
| June 30, 2021 | 26.64B |
| March 31, 2021 | 25.56B |
| December 31, 2020 | 24.69B |
| September 30, 2020 | 23.15B |
| June 30, 2020 | 22.17B |
| March 31, 2020 | 22.72B |
| December 31, 2019 | 22.45B |
| September 30, 2019 | 22.36B |
| June 30, 2019 | 22.36B |
| March 31, 2019 | 22.32B |
| December 31, 2018 | 22.13B |
| September 30, 2018 | 22.28B |
| June 30, 2018 | 23.20B |
| March 31, 2018 | 24.69B |
| Date | Value |
|---|---|
| December 31, 2017 | 26.11B |
| September 30, 2017 | 27.48B |
| June 30, 2017 | 28.47B |
| March 31, 2017 | 29.10B |
| December 31, 2016 | 30.39B |
| September 30, 2016 | 31.58B |
| June 30, 2016 | 32.37B |
| March 31, 2016 | 32.84B |
| December 31, 2015 | 32.64B |
| September 30, 2015 | 31.45B |
| June 30, 2015 | 29.19B |
| March 31, 2015 | 27.48B |
| December 31, 2014 | 24.89B |
| September 30, 2014 | 20.70B |
| June 30, 2014 | 17.44B |
| March 31, 2014 | 13.67B |
| December 31, 2013 | 11.20B |
| September 30, 2013 | 10.67B |
| June 30, 2013 | 10.31B |
| March 31, 2013 | 9.951B |
| December 31, 2012 | 9.702B |
| September 30, 2012 | 9.315B |
| June 30, 2012 | 9.010B |
| March 31, 2012 | 8.742B |
| December 31, 2011 | 8.385B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
22.17B
Minimum
Jun 2020
27.52B
Maximum
Jun 2022
25.63B
Average
27.08B
Median
Revenue (TTM) Benchmarks
| CymaBay Therapeutics Inc (DELISTED) | -- |
| Bristol-Myers Squibb Co | 45.53B |
| Merck & Co Inc | 61.40B |
| Pfizer Inc | 55.09B |
| Xilio Therapeutics Inc | -- |